Cellectar Biosciences (NASDAQ:CLRB) Shares Pass Below 200 Day Moving Average of $2.99

Shares of Cellectar Biosciences, Inc. (NASDAQ:CLRB) passed below its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $2.99 and traded as low as $2.08. Cellectar Biosciences shares last traded at $2.10, with a volume of 370,412 shares trading hands.

Cellectar Biosciences Stock Down 1.0 %

The company’s 50 day moving average price is $2.25 and its two-hundred day moving average price is $2.98. The firm has a market cap of $74.57 million, a PE ratio of -0.68 and a beta of 0.99.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the business. AIGH Capital Management LLC lifted its stake in shares of Cellectar Biosciences by 8.2% during the 2nd quarter. AIGH Capital Management LLC now owns 3,036,187 shares of the biopharmaceutical company’s stock worth $7,590,000 after acquiring an additional 231,270 shares during the last quarter. Rosalind Advisors Inc. lifted its position in shares of Cellectar Biosciences by 335.4% during the second quarter. Rosalind Advisors Inc. now owns 2,705,616 shares of the biopharmaceutical company’s stock worth $6,764,000 after purchasing an additional 2,084,138 shares during the last quarter. ADAR1 Capital Management LLC purchased a new stake in shares of Cellectar Biosciences during the fourth quarter valued at $3,817,000. Vanguard Group Inc. grew its holdings in shares of Cellectar Biosciences by 146.7% in the first quarter. Vanguard Group Inc. now owns 1,191,081 shares of the biopharmaceutical company’s stock worth $4,741,000 after purchasing an additional 708,191 shares during the last quarter. Finally, Worth Venture Partners LLC increased its stake in Cellectar Biosciences by 148.6% in the 4th quarter. Worth Venture Partners LLC now owns 693,909 shares of the biopharmaceutical company’s stock worth $1,922,000 after buying an additional 414,786 shares during the period. Institutional investors own 16.41% of the company’s stock.

Cellectar Biosciences Company Profile

Cellectar Biosciences, Inc, a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer.